Analyst: Zealand Pharma pipeline will be crucial
US-based investment bank Jefferies puts most stock in Zealand Pharma’s phase III trial of glepaglutide, a potential treatment for short bowel syndrome, when it comes to the company’s future plans.
by marketwire, translated by daniel pedersen
The potential of Zealand Pharma’s drug pipeline has been overlooked, according US-based investment bank Jefferies, which maintains its ”buy” recommendation for the biotech company.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Zealand Pharma reports higher costs in 2021
For subscribers
Zealand Pharma finishes phase III enrollment
For subscribers
Founder steps down from CEO role at Beta Bionics
For subscribers
